Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 39

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 39
---
 transfer technology or development out of Israel
or may not grant such approvals at all.

<div align='center'>19</div>

Furthermore, the consideration available to our
shareholders in a future transaction involving the transfer outside of Israel of technology or know-how developed with IIA funding (such
as a merger or similar transaction) may be reduced by any amounts that we are required to pay to the IIA. Any such mergers require IIA
approval to avoid penalties.

In addition to the above, any non-Israeli citizen,
resident or entity that, among other things, (i) becomes a holder of 5% or more of our share capital or voting rights, (ii) is entitled
to appoint one or more of our directors or our chief executive officer or (iii) serves as one of our directors or as our chief executive
officer (including holders of 25% or more of the voting power, equity or the right to nominate directors in such direct holder, if applicable)
is required to notify the IIA and undertake to comply with the rules and regulations applicable to the grant programs of the IIA, including
the restrictions on transfer described above. Such notification will be required in connection with the investment being made by an investor.

Risks Relating to our Common Stock

Our principal stockholders can significantly influence or control matters requiring a shareholder vote and other stockholders may not have the ability to influence corporate transactions. The sale of a large number of shares of Common Stock by our principal stockholders could depress the market price of our common stock.

Currently, our principal stockholders beneficially
own approximately 53% of our outstanding Common Stock. As a result, they may be able to influence or control the outcome of matters requiring
stockholder approval, including the election of directors and approval of significant corporate transactions. This concentration of ownership
may limit the ability of other stockholders to influence corporate actions. Additionally, sales of a substantial number of shares of
Common Stock by our principal stockholders in the public market, or the perception that such sales could occur, could depress the market
price of our Common Stock.

Our Common Stock is considered a “penny stock,” and any investment in our shares is considered to be a high-risk investment and is subject to restrictions on marketability. “Penny Stock” rules may make buying or selling our Common Stock difficult. Limitations upon Broker-Dealers Effecting Transactions in “Penny Stocks”.

Trading in our Common
Stock is subject to material limitations as a consequence